Vandria SA is a biopharmaceutical spin-off from Amazentis SA and was incorporated in Switzerland in 2021. The company discovers and develops novel small molecules that can effectively induce mitophagy to treat age-related and chronic diseases. Vandria is in the the IND-enabling stage with two lead candidates that have shown highly promising results in vitro and in vivo. The first clinical trials are expected to begin in Q2-2024
Through a unique drug discovery engine and a dedicated R&D team, we have developed and patented a range of novel small molecules that specifically can target the brain, muscle tissue, and other tissues.
Vandria is seeking investors to complete its investor syndicate for a Series A financing round which will be concluded in Q3-2023.
The disease focus is:
CNS: Mild Cognitive Impairment, ALS
Muscle: Sporadic Inclusion Body Myositis, Sarcopenia
Other: Inflammatory diseases, immuno-oncology
Vandria is open to discuss partnering opportunities with biotech and pharmaceutical companies, both in relation to our mitophagy inducer pipeline and our novel ferroptosis inhibitors.
Through a unique drug discovery engine and a dedicated R&D team, we have developed and patented a range of novel small molecules that specifically can target the brain, muscle tissue, and other tissues.
Vandria is seeking investors to complete its investor syndicate for a Series A financing round which will be concluded in Q3-2023.
The disease focus is:
CNS: Mild Cognitive Impairment, ALS
Muscle: Sporadic Inclusion Body Myositis, Sarcopenia
Other: Inflammatory diseases, immuno-oncology
Vandria is open to discuss partnering opportunities with biotech and pharmaceutical companies, both in relation to our mitophagy inducer pipeline and our novel ferroptosis inhibitors.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
